Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study

Detalhes bibliográficos
Autor(a) principal: Kamilos, Márcia Farina
Data de Publicação: 2021
Outros Autores: Aguiar, Lana Maria, Batista, Valéria Holmo, Roa, Cristiane Lima, Aguiar, Fernando Nalesso, Soares Júnior, José Maria, Baracat, Edmund Chada
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/192325
Resumo: OBJECTIVES: To assess the clinical response to and the histomorphometric effects of microablative fractional radiofrequency (MFR) in women with symptomatic vulvar lichen sclerosus (VLS). METHODS: This was a pilot study on the use of MFR for the treatment of VLS. Upon recruitment and at each treatment session, all participants were examined and each of their symptoms were rated on a visual analog scale. After the procedure, the participants completed a satisfaction questionnaire. We compared the morphometric findings of vulvar biopsies performed at enrollment and after the last treatment session. The participants were divided into three groups according to previous treatment with corticosteroids: G1, no previous treatment; G2, treated for up to 5 years; and G3, treated for 45 years. RESULTS: This study included 26 women. After two to three sessions, most participants in all groups became either ‘‘asymptomatic’’ or ‘‘much better’’ than before treatment and were ‘‘very satisfied’’ or ‘‘satisfied’’ with the intervention. Pruritus and burning sensation were the most frequently reported symptoms. Nearly 40% of the participants in all groups reported complete remission of symptoms. The improvement was rated as moderate or higher by 80%, 76%, and 66% of the women in groups 1, 2, and 3, respectively. The improvement of symptoms persisted for 11 months (range, 7–16 months), on average, after the treatment. Type III collagen concentration significantly increased and was associated with important symptom improvement. Tissue trophism and vascularization also increased but did not reach statistical significance, probably because of the small number of cases. CONCLUSIONS: MFR may be an effective and safe treatment for symptomatic VLS.
id USP-19_5d1fa5667fdc83e8d59f7dabdc77025d
oai_identifier_str oai:revistas.usp.br:article/192325
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot studyVulvar Lichen SclerosusVulvar ItchingAtrophyRadiofrequency TreatmentCorticosteroidsOBJECTIVES: To assess the clinical response to and the histomorphometric effects of microablative fractional radiofrequency (MFR) in women with symptomatic vulvar lichen sclerosus (VLS). METHODS: This was a pilot study on the use of MFR for the treatment of VLS. Upon recruitment and at each treatment session, all participants were examined and each of their symptoms were rated on a visual analog scale. After the procedure, the participants completed a satisfaction questionnaire. We compared the morphometric findings of vulvar biopsies performed at enrollment and after the last treatment session. The participants were divided into three groups according to previous treatment with corticosteroids: G1, no previous treatment; G2, treated for up to 5 years; and G3, treated for 45 years. RESULTS: This study included 26 women. After two to three sessions, most participants in all groups became either ‘‘asymptomatic’’ or ‘‘much better’’ than before treatment and were ‘‘very satisfied’’ or ‘‘satisfied’’ with the intervention. Pruritus and burning sensation were the most frequently reported symptoms. Nearly 40% of the participants in all groups reported complete remission of symptoms. The improvement was rated as moderate or higher by 80%, 76%, and 66% of the women in groups 1, 2, and 3, respectively. The improvement of symptoms persisted for 11 months (range, 7–16 months), on average, after the treatment. Type III collagen concentration significantly increased and was associated with important symptom improvement. Tissue trophism and vascularization also increased but did not reach statistical significance, probably because of the small number of cases. CONCLUSIONS: MFR may be an effective and safe treatment for symptomatic VLS.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2021-11-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/19232510.6061/clinics/2021/e2567Clinics; Vol. 76 (2021); e2567Clinics; v. 76 (2021); e2567Clinics; Vol. 76 (2021); e25671980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/192325/177214Copyright (c) 2021 Clinicsinfo:eu-repo/semantics/openAccessKamilos, Márcia Farina Aguiar, Lana Maria Batista, Valéria Holmo Roa, Cristiane Lima Aguiar, Fernando Nalesso Soares Júnior, José Maria Baracat, Edmund Chada 2023-07-06T13:04:03Zoai:revistas.usp.br:article/192325Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:03Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
title Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
spellingShingle Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
Kamilos, Márcia Farina
Vulvar Lichen Sclerosus
Vulvar Itching
Atrophy
Radiofrequency Treatment
Corticosteroids
title_short Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
title_full Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
title_fullStr Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
title_full_unstemmed Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
title_sort Microablative fractional radiofrequency as a therapeutic option for vulvar lichen sclerosus: a pilot study
author Kamilos, Márcia Farina
author_facet Kamilos, Márcia Farina
Aguiar, Lana Maria
Batista, Valéria Holmo
Roa, Cristiane Lima
Aguiar, Fernando Nalesso
Soares Júnior, José Maria
Baracat, Edmund Chada
author_role author
author2 Aguiar, Lana Maria
Batista, Valéria Holmo
Roa, Cristiane Lima
Aguiar, Fernando Nalesso
Soares Júnior, José Maria
Baracat, Edmund Chada
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Kamilos, Márcia Farina
Aguiar, Lana Maria
Batista, Valéria Holmo
Roa, Cristiane Lima
Aguiar, Fernando Nalesso
Soares Júnior, José Maria
Baracat, Edmund Chada
dc.subject.por.fl_str_mv Vulvar Lichen Sclerosus
Vulvar Itching
Atrophy
Radiofrequency Treatment
Corticosteroids
topic Vulvar Lichen Sclerosus
Vulvar Itching
Atrophy
Radiofrequency Treatment
Corticosteroids
description OBJECTIVES: To assess the clinical response to and the histomorphometric effects of microablative fractional radiofrequency (MFR) in women with symptomatic vulvar lichen sclerosus (VLS). METHODS: This was a pilot study on the use of MFR for the treatment of VLS. Upon recruitment and at each treatment session, all participants were examined and each of their symptoms were rated on a visual analog scale. After the procedure, the participants completed a satisfaction questionnaire. We compared the morphometric findings of vulvar biopsies performed at enrollment and after the last treatment session. The participants were divided into three groups according to previous treatment with corticosteroids: G1, no previous treatment; G2, treated for up to 5 years; and G3, treated for 45 years. RESULTS: This study included 26 women. After two to three sessions, most participants in all groups became either ‘‘asymptomatic’’ or ‘‘much better’’ than before treatment and were ‘‘very satisfied’’ or ‘‘satisfied’’ with the intervention. Pruritus and burning sensation were the most frequently reported symptoms. Nearly 40% of the participants in all groups reported complete remission of symptoms. The improvement was rated as moderate or higher by 80%, 76%, and 66% of the women in groups 1, 2, and 3, respectively. The improvement of symptoms persisted for 11 months (range, 7–16 months), on average, after the treatment. Type III collagen concentration significantly increased and was associated with important symptom improvement. Tissue trophism and vascularization also increased but did not reach statistical significance, probably because of the small number of cases. CONCLUSIONS: MFR may be an effective and safe treatment for symptomatic VLS.
publishDate 2021
dc.date.none.fl_str_mv 2021-11-09
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/192325
10.6061/clinics/2021/e2567
url https://www.revistas.usp.br/clinics/article/view/192325
identifier_str_mv 10.6061/clinics/2021/e2567
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/192325/177214
dc.rights.driver.fl_str_mv Copyright (c) 2021 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 76 (2021); e2567
Clinics; v. 76 (2021); e2567
Clinics; Vol. 76 (2021); e2567
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222765742030848